Oppenheimer & Co. Inc. Purchases 31,559 Shares of Novavax, Inc. (NASDAQ:NVAX)

Oppenheimer & Co. Inc. lifted its stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 262.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 43,573 shares of the biopharmaceutical company's stock after acquiring an additional 31,559 shares during the period. Oppenheimer & Co. Inc.'s holdings in Novavax were worth $350,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVAX. Spire Wealth Management acquired a new position in shares of Novavax during the 4th quarter worth about $29,000. KBC Group NV boosted its position in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 3,917 shares during the period. TigerOak Management L.L.C. bought a new stake in shares of Novavax in the fourth quarter valued at approximately $86,000. Beirne Wealth Consulting Services LLC grew its stake in shares of Novavax by 65.0% in the fourth quarter. Beirne Wealth Consulting Services LLC now owns 16,500 shares of the biopharmaceutical company's stock worth $133,000 after acquiring an additional 6,500 shares during the last quarter. Finally, US Bancorp DE increased its position in Novavax by 3,538.8% during the third quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company's stock worth $155,000 after acquiring an additional 11,961 shares during the period. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Novavax

In other Novavax news, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the transaction, the director now owns 14,770 shares in the company, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James F. Young sold 5,400 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total value of $43,200.00. Following the sale, the director now owns 51,760 shares in the company, valued at $414,080. The trade was a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock worth $119,641 over the last ninety days. Corporate insiders own 1.00% of the company's stock.

Remove Ads

Novavax Stock Performance

NASDAQ NVAX traded down $0.26 during trading on Tuesday, reaching $7.92. 3,192,572 shares of the company traded hands, compared to its average volume of 8,048,072. Novavax, Inc. has a 1-year low of $3.81 and a 1-year high of $23.86. The stock's 50 day moving average price is $8.46 and its two-hundred day moving average price is $9.74. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -3.50, a P/E/G ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same quarter last year, the company earned ($1.44) earnings per share. Equities research analysts expect that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. TD Cowen raised shares of Novavax to a "hold" rating in a report on Thursday, February 27th. BTIG Research began coverage on Novavax in a research report on Friday, February 28th. They set a "buy" rating and a $19.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and set a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Novavax presently has an average rating of "Hold" and a consensus price target of $18.00.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.